191 related articles for article (PubMed ID: 36522191)
1. PET/CT in Non-Hodgkin Lymphoma: An Update.
Zanoni L; Bezzi D; Nanni C; Paccagnella A; Farina A; Broccoli A; Casadei B; Zinzani PL; Fanti S
Semin Nucl Med; 2023 May; 53(3):320-351. PubMed ID: 36522191
[TBL] [Abstract][Full Text] [Related]
2. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
3. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
4.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
5.
Barrington SF; Johnson PWM
J Nucl Med; 2017 Oct; 58(10):1539-1544. PubMed ID: 28798034
[TBL] [Abstract][Full Text] [Related]
6. Distinct FDG PET/CT avidity among newly diagnosed intravascular large B-cell lymphoma patients: a descriptive observational study.
Zhao D; Zhang Y; Zhu W; Huo L; Zhou D; Wang W; Wei C; Zhang W
Ann Hematol; 2024 Feb; 103(2):545-552. PubMed ID: 37932469
[TBL] [Abstract][Full Text] [Related]
7. Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.
Zanoni L; Mattana F; Calabrò D; Paccagnella A; Broccoli A; Nanni C; Fanti S
Eur J Radiol; 2021 Aug; 141():109793. PubMed ID: 34148014
[TBL] [Abstract][Full Text] [Related]
8. Utility of
Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK
Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
10.
Ruff A; Ballard HJ; Pantel AR; Namoglu EC; Hughes ME; Nasta SD; Chong EA; Bagg A; Ruella M; Farwell MD; Svoboda J; Sellmyer MA
Mol Imaging Biol; 2021 Dec; 23(6):818-826. PubMed ID: 34231105
[TBL] [Abstract][Full Text] [Related]
11. Follicular lymphoma transforming into diffuse large B-cell lymphoma in spleen: Simultaneous appearance of both on
Makis W; Ciarallo A; Petrogiannis-Haliotis T; Rosenberg A; Probst S
Clin Imaging; 2017; 43():88-92. PubMed ID: 28259031
[TBL] [Abstract][Full Text] [Related]
12.
Albano D; Durmo R; Treglia G; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):137-146. PubMed ID: 32029397
[TBL] [Abstract][Full Text] [Related]
13. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
14. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
15. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
16. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
Barrington SF; Kluge R
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
[TBL] [Abstract][Full Text] [Related]
17. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
18. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
19. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
McCarten KM; Nadel HR; Shulkin BL; Cho SY
Pediatr Radiol; 2019 Oct; 49(11):1545-1564. PubMed ID: 31620854
[TBL] [Abstract][Full Text] [Related]
20. Integration of PET in DLBCL.
Lewis KL; Trotman J
Semin Hematol; 2023 Nov; 60(5):291-304. PubMed ID: 38326144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
